# Lamin A/C as a Molecular Link Between Nuclear Organization, Chromatin Dynamics, and Tumor Progression

**Authors:** Cecilia Foglini, Katia Scotlandi, Michela Pasello

PMC · DOI: 10.3390/cells15060501 · 2026-03-11

## TL;DR

Lamin A/C connects nuclear structure and function, influencing cancer progression in complex, context-dependent ways.

## Contribution

Lamin A/C is redefined as a dynamic regulator linking nuclear mechanics, chromatin dynamics, and tumor progression.

## Key findings

- Lamin A/C regulates chromatin organization and transcription by linking nuclear mechanics and epigenetics.
- Its role in cancer is context-dependent, leading to varied prognostic associations across tumor types.
- Lamin A/C functions as a nuclear rheostat, balancing cell deformability and genome stability in tumor progression.

## Abstract

What are the main findings?
Lamin A/C is a dynamic mechano-epigenetic regulator that links nuclear mechanics with chromatin organization and transcription.In cancer, lamin A/C functions in a strongly context-dependent manner, yielding heterogeneous and sometimes opposing prognostic associations across tumor types.

Lamin A/C is a dynamic mechano-epigenetic regulator that links nuclear mechanics with chromatin organization and transcription.

In cancer, lamin A/C functions in a strongly context-dependent manner, yielding heterogeneous and sometimes opposing prognostic associations across tumor types.

What are the implications of the main findings?
Lamin A/C might be viewed as a nuclear rheostat that regulates tumor cell behavior along a spectrum from deformability and plasticity to mechanical robustness and genome stability.Clinical translation requires context-dependent strategies that use lamin A/C features for patient stratification and target its associated pathways for treatment while preserving normal tissue function.

Lamin A/C might be viewed as a nuclear rheostat that regulates tumor cell behavior along a spectrum from deformability and plasticity to mechanical robustness and genome stability.

Clinical translation requires context-dependent strategies that use lamin A/C features for patient stratification and target its associated pathways for treatment while preserving normal tissue function.

Lamin A/C is emerging as a promising candidate regulator at the intersection of nuclear mechanics, chromatin organization, and gene regulation, linking structure and regulation, mechanics and epigenetics, constraint and plasticity. Lamin A/C was previously considered a static structural scaffold; however, it is now recognized as a dynamic component of nuclear organization that links physical cues to epigenetic and transcriptional states. Lamin A/C regulates three-dimensional genome structure, constrains chromatin mobility, and influences cell transitions between plastic and committed states through its interactions with heterochromatin at the nuclear periphery and active chromatin domains in the nuclear interior. In cancer, these functions appear to be dependent on the context. Lamin A/C has been implicated in crucial biological processes, including invasion, survival under mechanical stress, lineage plasticity, and therapeutic response. Its prognostic value varies across tumor types. This heterogeneity indicates that lamin A/C does not function as a traditional oncogene or oncosuppressor; instead, it operates as a nuclear rheostat, influencing the behavior and development of tumor cells. This review examines the potential clinical benefits of lamin A/C while considering its implications for normal tissue functions. It aims to improve understanding of cellular adaptability and vulnerability in cancer through the exploration of lamin A/C biology.

## Linked entities

- **Genes:** Lmna (lamin A/C) [NCBI Gene 100757316]
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, AKT2 (AKT serine/threonine kinase 2) [NCBI Gene 208] {aka HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, CCR4 (C-C motif chemokine receptor 4) [NCBI Gene 1233] {aka CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099}, SUV39H1 (SUV39H1 histone lysine methyltransferase) [NCBI Gene 6839] {aka H3-K9-HMTase 1, KMT1A, MG44, SUV39H}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, TMPO (thymopoietin) [NCBI Gene 7112] {aka CMD1T, LAP2, LEMD4, PRO0868, TP}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, SMURF2 (SMAD specific E3 ubiquitin protein ligase 2) [NCBI Gene 64750], CBX5 (chromobox 5) [NCBI Gene 23468] {aka HEL25, HP1, HP1A, HP1alpha}, KAT8 (lysine acetyltransferase 8) [NCBI Gene 84148] {aka LIGOWS, MOF, MYST1, ZC2HC8, hMOF}, RCE1 (Ras converting CAAX endopeptidase 1) [NCBI Gene 9986] {aka FACE2, RCE1A, RCE1B}, SYNE1 (spectrin repeat containing nuclear envelope protein 1) [NCBI Gene 23345] {aka 8B, AMC3, AMCM, ARCA1, C6orf98, CPG2}, UBE2I (ubiquitin conjugating enzyme E2 I) [NCBI Gene 7329] {aka C358B7.1, P18, UBC9}, CNOT1 (CCR4-NOT transcription complex subunit 1) [NCBI Gene 23019] {aka AD-005, CDC39, HPE12, NOT1, NOT1H, VIBOS}, LEMD2 (LEM domain nuclear envelope protein 2) [NCBI Gene 221496] {aka CTRCT42, LEM2, MARUPS, NET25, dJ482C21.1}, ZMPSTE24 (zinc metallopeptidase STE24) [NCBI Gene 10269] {aka FACE-1, FACE1, HGPS, PRO1, RSDM1, STE24}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, HDAC3 (histone deacetylase 3) [NCBI Gene 8841] {aka HD3, KDAC3, RPD3, RPD3-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TPX2 (TPX2 microtubule nucleation factor) [NCBI Gene 22974] {aka C20orf1, C20orf2, DIL-2, DIL2, FLS353, GD:C20orf1}, SRF (serum response factor) [NCBI Gene 6722] {aka MCM1}, SUMO1 (small ubiquitin like modifier 1) [NCBI Gene 7341] {aka DAP1, GMP1, OFC10, PIC1, SMT3, SMT3C}, Lmna (lamin A) [NCBI Gene 16905] {aka Dhe}, ANKRD2 (ankyrin repeat domain 2) [NCBI Gene 26287] {aka ARPP}, RNF123 (ring finger protein 123) [NCBI Gene 63891] {aka FP1477, KPC1}, GATA4 (GATA binding protein 4) [NCBI Gene 2626] {aka ASD2, TACHD, TOF, VSD1}, LBR (lamin B receptor) [NCBI Gene 3930] {aka C14SR, DHCR14B, LMN2R, PHA, PHASK, TDRD18}, HECW2 (HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2) [NCBI Gene 57520] {aka NDHSAL, NEDL2}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, ZNF239 (zinc finger protein 239) [NCBI Gene 8187] {aka HOK-2, MOK2}, BANF1 (barrier to autointegration nuclear assembly factor 1) [NCBI Gene 8815] {aka BAF, BCRP1, D14S1460, NGPS}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, EHMT2 (euchromatic histone lysine methyltransferase 2) [NCBI Gene 10919] {aka BAT8, C6orf30, G9A, GAT8, KMT1C, NG36}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SYNE2 (spectrin repeat containing nuclear envelope protein 2) [NCBI Gene 23224] {aka EDMD5, KASH2, NUA, NUANCE, Nesp2, Nesprin-2}, CIMAP2 (ciliary microtubule associated protein 2) [NCBI Gene 163747] {aka C1orf177, LEM, LEXM}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, RARG (retinoic acid receptor gamma) [NCBI Gene 5916] {aka NR1B3, RARC, RARgamma}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, LMNB1 (lamin B1) [NCBI Gene 4001] {aka ADLD, LMN, LMN2, LMNB, MCPH26}, LEMD3 (LEM domain containing 3) [NCBI Gene 23592] {aka MAN1}, ICMT (isoprenylcysteine carboxyl methyltransferase) [NCBI Gene 23463] {aka HSTE14, MST098, MSTP098, PCCMT, PCMT, PPMT}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CASP6 (caspase 6) [NCBI Gene 839] {aka CSP-6, MCH2, caspase-6}
- **Diseases:** inflammation (MESH:D007249), inherited diseases (MESH:D030342), osteosarcoma (MESH:D012516), Ovarian carcinoma (MESH:D010051), Colon (MESH:D003108), metastatic (MESH:D000092182), restrictive dermopathy (MESH:C536920), lymphoma (MESH:D008223), other (MESH:D058497), colon carcinoma (MESH:D003110), Breast carcinoma (MESH:D001943), cancer (MESH:D009369), glioblastoma (MESH:D005909), neuroblastoma (MESH:D009447), Ewing sarcoma (MESH:D012512), Hutchinson-Gilford progeria syndrome (MESH:D011371), epithelial ovarian cancer (MESH:D000077216), laminopathies (MESH:D000083083), prostate (MESH:D011472), breast, colon, liver, lung, ovary, thyroid, and prostate cancers (MESH:D061325), pancreatic adenocarcinoma (MESH:D010190), colon cancer (MESH:D015179), fibrosarcoma (MESH:D005354), lung and thyroid carcinomas (MESH:C567034), hepatocellular carcinoma (MESH:D006528), LADs (MESH:D018886), gastric carcinoma (MESH:D013274), non-small cell lung carcinoma (MESH:D002289), toxicity (MESH:D064420), pancreatic intraductal papillary neoplasms (MESH:D000077779), leukemia (MESH:D007938), lung cancer (MESH:D008175), Dunnigan-type familial partial lipodystrophy (MESH:D052496), tumorigenesis (MESH:D063646), metastasis (MESH:D009362), prostate cancer (MESH:D011471), gastrointestinal cancers (MESH:D005770), nuclear abnormalities (MESH:C563333), Emery-Dreifuss muscular dystrophy (MESH:D020389), injury to (MESH:D014947), nasopharyngeal carcinoma (MESH:D000077274), pleural adenocarcinoma (MESH:D000230)
- **Chemicals:** FN (MESH:C007768), glucose (MESH:D005947), ROS (MESH:D017382), doxorubicin (MESH:D004317), verteporfin (MESH:D000077362), lipid (MESH:D008055), cisplatin (MESH:D002945), SCH66336 (MESH:C115354), mevalonate (MESH:D008798), 13a (-), mevinolin (MESH:D008148)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** S22A, Ser392, S392A, T19A, Ser390, S392D
- **Cell lines:** U2OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024949/full.md

---
Source: https://tomesphere.com/paper/PMC13024949